Melphalan Sun

Melphalan, the active ingredient in Melphalan Sun, is an alkylating agent presented as a sterile solution for intraarterial and intravenous use. It is used in the treatment of certain cancers such as multiple myeloma, ovarian cancer and melanoma in adult patients.

GNH USA supplies Melphalan Sun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Melphalan is an alkylating chemotherapy agent used in the management of hematologic and solid tumors.

Multiple myeloma: reduces malignant plasma cells and prolongs survival. Ovarian cancer: contributes to tumor shrinkage and disease control. Melanoma: used in combination regimens to inhibit tumor growth.

Melphalan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: frequent episodes of stomach upset. - Vomiting: occasional to persistent emesis. - Fatigue: general tiredness and weakness. - Myelosuppression: reduced white blood cells, red cells, and platelets. - Mucositis: inflammation of the mouth and gastrointestinal lining.

Serious or Rare Side Effects: - Secondary malignancies: development of new cancers. - Severe infection: due to profound neutropenia. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Renal impairment: decreased kidney function. - Cardiotoxicity: arrhythmias or heart failure.

When using Melphalan, careful monitoring and specific precautions are recommended to minimize risks.

- Baseline blood counts: obtain complete blood count before initiating therapy. - Renal function: assess serum creatinine and adjust if impaired. - Hepatic function: monitor liver enzymes for potential toxicity. - Pregnancy: avoid use in pregnant patients; teratogenic risk is unknown. - Concomitant myelosuppressive agents: use with caution to prevent excessive bone‑marrow suppression. - Store at ambient temperature: keep below 25°C, protect from moisture and light, retain in original container.

Melphalan can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid): - Live vaccines: increased risk of infection due to immunosuppression. - High-dose radiation therapy: additive bone‑marrow toxicity. - Strong CYP inducers: may reduce plasma levels (e.g., rifampin).

Moderate Interactions (Monitor Closely): - Antiemetics (e.g., ondansetron): may affect melphalan clearance. - Antifungals (e.g., fluconazole): can increase melphalan exposure. - NSAIDs: may exacerbate renal toxicity. - Granulocyte colony‑stimulating factors: used to mitigate myelosuppression, monitor blood counts.